Creative Biolabs bends efforts for years to offering high-level services in the field of antibody on a worldwide scale, aiming to facilitate the research institutes and pharmaceutical manufacturers with their process of drug development and to improve precision medicine.
With characteristics of enhanced targeting capability, good curative effects, and few side effects, antibodies are important sub-sectors of the biomedical industry, and the market share continues to rise. To help scientists explore the full potential of recombinant antibody (rAb), Creative Biolabs is dedicated to offering a coverage of rAb discovery and manufacturing services to worldwide customers in both academia and industry fields.
Recombinant antibodies are antibody fragments produced by using rAb coding genes as a source and display technology, delivering high reproducibility, specificity and scalability. As a pioneer in rAb development, Creative Biolabs has developed proprietary procedures for Hi-Affi™ rAb production including anti-idiotypic antibody, rabbit monoclonal antibody, chicken IgY antibody, blocking antibody, scFv fragment antibody, Fab fragment antibody, etc. These kinds of Hi-Affi™ rAb share the advantages of high purity (>98%) and affinity, reproducibility, complete condition control, as well as short production time and no animals required.
As an important part of rAb, the research on therapeutic antibody has entered a rapid growth phase with their potential and unprecedented success recognized. A full range of therapeutic antibodies can be found in Creative Biolabs available for research of a number of diseases, including but not limited to cancers, immune disorders, and various infections.
“Fc-mediated mechanisms CDC (complement-dependent cytotoxicity) is considered to be particularly important for successful therapeutic intervention” Introduced by a senior scientist of Creative Biolabs, “We are proud to offer our customers a novel CDC-enhanced antibody production technology named Crea-Tag™, which has been confirmed to significantly enhance the CDC effect of antibodies.”
Apart from CDC-enhanced antibody, Creative Biolabs also excels in other therapeutic antibodies such as mouse antibody, chimeric antibody, humanized antibody, antibody-dependent cellular cytotoxicity (ADCC)-enhanced antibody, etc.
Despite the aforementioned, single-domain antibodies (SdAbs) derived from the variable regions of heavy chain of Camelidae immunoglobulins, are also a kind of rAb considered of great value for research and therapeutics use. Creative Biolabs provides the most complete collection of SdAb products with the assistance of proprietary SdAb platform, which allows rapid generation and large-scale production of high affinity novel biological therapeutics that have great potential in a wide range of human diseases.
Other engineered antibodies, such as bispecific antibody, immunotoxin, immunocytokine, intrabody and antibody-drug conjugate are all hot rAb products provided by Creative Biolabs.
Believing that a custom-service-centered business model is important for optimizing the drug development process and leveraging accessible resources, Creative Biolabs keeps upgrading the list of rAb products and relevant services, and has built a team of experts with solid knowledge to assist global clients. Further information can be found on: https://www.creativebiolabs.net.
About Creative Biolabs
Established in 2004, Creative Biolabs was founded by scientists who are devoted to the conquering of cancer. With more than a decade of exploration and expansion, the current research and service capacity covers engineered antibody, soluble T cell receptor, therapeutic protein, glyco-engineering antibody, antibody-like scaffold protein, MHC Tetramer, etc.